NIKKEI 225
38,329.39 +777.23 (+2.07%) HANG SENG
17,133.59 +304.66 (+1.81%) CRUDE OIL
83.33 -0.03 (-0.04%) GOLD FUTURES
2,335.00 -7.10 (-0.30%) DOW
38,503.69 +263.71 (+0.69%) Bitcoin GBP
53,518.00 -96.29 (-0.18%)
Greenwich LifeSciences, Inc. (GLSI)
After hours:
| Previous close | 12.69 |
| Open | 12.59 |
| Bid | 0.00 x 0 |
| Ask | 13.31 x 100 |
| Day's range | 12.50 - 13.38 |
| 52-week range | 7.58 - 21.44 |
| Volume | |
| Avg. volume | 52,346 |
| Market cap | 169.222M |
| Beta (5Y monthly) | 3.19 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.69 |
| Earnings date | 22 May 2024 - 27 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 36.00 |
Insider MonkeyInsiders are Piling into These 10 Healthcare Stocks in 2024
In this article, we will take a detailed look at Insiders are Piling into These 10 Healthcare Stocks in 2024. For a quick overview of such stocks, read our article Insiders are Piling into These 5 Healthcare Stocks in 2024. Healthcare investors were nervous when 2024 started, since election years usually don’t bode well for healthcare stocks. But […]
GlobeNewswireGreenwich LifeSciences Extends Lock-up of Directors and Officers to June 30, 2025
STAFFORD, Texas, March 13, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that its Board of Directors has extended the lock-up of the shares owned by the Company's directors, officers, and existing pre-IPO investors to June 30, 2025 which is approximately 57 mont
- GlobeNewswire
Greenwich LifeSciences Partners with GEICAM in Spain & Conducts First Site Initiation Visits in Europe
STAFFORD, Texas, March 12, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the initiation of the first clinical sites in Europe in collaboration with GEICAM in Spain. The Company has partnered with GEICAM, the largest academic breast cancer research network in Spa
